The first batch of 10,000 doses of 2DG drugs for curing COVID-19 sufferers can be launched early next week and will likely be given to sufferers, says DRDO officers.
At a time when nation battles with the second wave of coronavirus, the primary batch of 10,000 doses of 2DG drugs for curing COVID-19 sufferers can be launched early next week and will likely be given to sufferers, DRDO officers knowledgeable on Friday.
“The drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr Anant Narayan Bhatt,” officers stated.
Earlier within the day, Karnataka Health Minister Dr Ok Sudhakar had stated that DRDO 2DG drug for Covid-19 might act as a game-changer in nation’s battle in opposition to the pandemic.
“The 2-DG drug developed by DRDO is a big breakthrough and could be a game-changer in the battle against pandemic as it helps in faster recovery of hospitalised patients and reduces oxygen dependence,” Sudhakar was quoted as saying in an announcement issued by his workplace.
ALSO READ |Â Govt approves procurement of 1.5 lakh models of DRDO’s Oxycare system
Â
The Minister had visited the DRDO campus within the metropolis the place scientists briefed him concerning the ongoing efforts on the premier analysis organisation to discover options to sort out the pandemic.
About the 2-DG (2-deoxy-D-glucose), an anti-COVID-19 therapeutic software of the drug, the assertion learn that it has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddys Laboratories (DRL), Hyderabad.
Clinical trial outcomes have proven that this molecule helps in sooner restoration of hospitalised sufferers and reduces supplemental oxygen dependence.
Higher proportion of sufferers handled with 2-DG confirmed RT-PCR unfavourable conversion in COVID sufferers. The drug can be of profit to the folks affected by COVID-19, the assertion learn.
In April 2020, through the first wave of the pandemic, INMAS-DRDO scientists carried out laboratory experiments with the assistance of Centre for Cellular and Molecular Biology (CCMB), Hyderabad, and located that this molecule works successfully in opposition to SARS-CoV-2 virus and inhibits the viral development, in accordance to the assertion.
